Skip to content

Accuracy Assessment of a Novel Gas Detection Approach in Dyslipidemia Diagnosis

Accuracy Validation Study of a Novel Gas Detection Method for Dyslipidemia

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06486857
Enrollment
1000
Registered
2024-07-05
Start date
2024-07-01
Completion date
2026-12-30
Last updated
2024-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemias, Gas Detection Method

Brief summary

This study aims to validate the feasibility and accuracy of a novel gas detection method for dyslipidemia screening by analyzing the lipid profile of human breath metabolites. It explores a simple, rapid, and non-invasive method for screening dyslipidemia. The application prospects of this method are broad; it can be used not only for early screening and monitoring of dyslipidemia in hospitals and communities, providing strong support for the prevention of cardiovascular diseases, but also for the routine monitoring and treatment effectiveness evaluation of patients with hyperlipidemia, offering a scientific basis for personalized treatment plans. This study not only has profound scientific value but also provides a theoretical basis for the development of subsequent new clinical testing methods.

Interventions

DIAGNOSTIC_TESTa novel gas detection method for dyslipidemia screening

Multidimensional Mass Spectrometry Technologies Based on Exhaled Metabolic Fingerprint Spectra for Dyslipidemia Detection

Sponsors

Beijing Anzhen Hospital
Lead SponsorOTHER

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Age ≥ 18 years 2. Voluntarily signed the informed consent form

Exclusion criteria

1. Patients with lung cancer, asthma, chronic obstructive pulmonary disease, pulmonary cystic fibrosis, or acute respiratory distress syndrome 2. Women who are pregnant or breastfeeding 3. Patients with chronic kidney disease (GFR \< 60 ml/min) or cirrhosis 4. Individuals unable to cooperate with the collection of exhaled gas samples

Design outcomes

Primary

MeasureTime frame
accuracy of cholesterol testingwithin 1 week day of sample collection

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026